Conv. Plasma
Nigella Sativa
Peg.. Lambda
Vitamin A
Vitamin C
Vitamin D

Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Curcumin COVID-19 studies. Studies typically use advanced formulations for greatly improved bioavailability. Recent:
Submit updates/corrections.
Jun 27
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis)
Curcumin for COVID-19: real-time meta analysis of 18 studies
Details   • Statistically significant improvements are seen for mortality, hospitalization, recovery, and viral clearance. 11 studies from 10 independent teams in 6 different countries show statistically significant improvements in isolation (7 for..
Jun 6
Early Askari et al., Trials, doi:10.1186/s13063-022-06375-w
no recov., ↑125.0%, p=0.58
The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial
Details   Small RCT 46 outpatients in Iran, 23 treated with curcimin-piperine, showing no significant differences in recovery. 1000mg curcumin and 10mg piperine/day for 14 days.
May 19
Late Hellou et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337
NEWS2, ↓76.7%, p=0.04
Effect of ArtemiC in patients with COVID-19: A Phase II prospective study
Details   RCT 50 hospitalized patients in Israel, 33 treated with curcumin, vitamin C, artemisinin, and frankincense oral spray, showing improved recovery with treatment.
May 1
In Silico Nag et al., Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552
In Silico
Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
Details   In Silico study showing showing significant inhibitory potential of curcumin for omicron.
May 1
Early Khan et al., Frontiers in Pharmacology
no recov., ↓33.3%, p=0.15
Oral co-supplementation of curcumin, quercetin and vitamin D3 as adjuvant therapy for mild to moderate symptoms of COVID-19 -Results from an open-label, pilot randomized controlled trial
Details   RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). Only the abstract is c..
Apr 28
Meta Kow et al., Phytotherapy Research, doi:10.1002/ptr.7468
death, ↓77.0%, p=0.002
The effect of curcumin on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials
Details   Meta analysis of 3 curcumin RCTs showing lower mortality with treatment. Author notes the small sample sizes of the included trials.
Apr 9
In Vitro Leka et al., Phytotherapy Research, doi:10.1002/ptr.7463 (In Vitro)
In Vitro
In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds
Details   In Vitro study showing antiviral activity of curcumin longa, with protection against SARS-CoV-2-induced cytopathic effects at a concentration of 3.125μg/ml.
Mar 25
Late Sankhe et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824
death, ↓85.7%, p=0.24
A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
Details   RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurco..
Mar 22
Late Thomas et al., COVID, doi:10.3390/covid2040031
improv., ↓44.3%, p=0.02
A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study
Details   RCT 147 long COVID patients in the UK, 56 treated with a phytochemical-rich concentrated food capsule, showing improved recovery with treatment. Treatment included curcumin, bioflavonoids, chamomile, ellagic acid, and resveratrol.
Feb 28
PrEPPEP Shehab et al., Tropical Journal of Pharmaceutical Research, doi:10.4314/tjpr.v21i2.13
severe case, ↓42.4%, p=0.55
Immune-boosting effect of natural remedies and supplements on progress of, and recovery from COVID-19 infection
Details   Retrospective survey-based analysis of 349 COVID-19 patients, showing a lower risk of severe cases with vitamin D, zinc, turmeric, and honey prophylaxis in unadjusted analysis, without statistical significance. REC/UG/2020/03.
Feb 22
Late Hartono et al., Pharmacognosy Journal, doi:10.5530/pj.2022.14.27
viral+, ↓53.3%, p<0.0001
The Effect of Curcumin and Virgin Coconut Oil Towards Cytokines Levels in COVID-19 Patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia
Details   RCT with 30 patients treated with curcumin and virgin coconut oil (VCO), and 30 SOC patients in Indonesia, showing faster viral clearance with treatment. Treatment also reduced IL-1β, IL-2, IL-6, IL-18, and IFN-β levels. VCO improves the..
Feb 4
In Silico Rampogu et al., International Journal of Molecular Sciences, doi:10.3390/ijms23031771
In Silico
Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2
Details   In Silico molecular dynamics simulation study finding a curcumin analogue (curA) as a promising dual inhibitor for SARS-CoV-2.
Jan 28
Late Kartika et al., ICE on IMERI, 2021 (Preprint)
hosp. time, ↓41.0%, p=0.048
Curcumin as adjuvant Therapy in Mild - Moderate Covid 19
Details   Retrospective 246 hospitalized patients in Indonesia, 136 treated with curcumin, showing shorter hospitalization time with treatment. All patients received vitamin C, D, and zinc.
Jan 21
In Vitro Goc et al., European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022 (In Vitro)
In Vitro
Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants
Details   In Vitro study testing combinations of plant extracts and micronutrients with several variants of SARS-CoV-2. A combination of vitamin C, N-acetylcysteine, curcumin, quercetin, resveratrol, theaflavin, naringenin, baicalin, and broccoli e..
Jan 17
Late Asadirad et al., Phytotherapy Research, doi:10.1002/ptr.7375
death, ↓25.9%, p=0.74
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial
Details   RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.
Jan 12
Late Honarkar Shafie et al., Phytotherapy Research, doi:10.1002/ptr.7374
hosp. time, ↓28.9%, p=0.22
Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial
Details   RCT 48 hospitalized patients in Iran, 24 treated with nanocurcumin, showing lower hospitalization time with treatment. The number of patients shown in Table 3 (31 and 27 for each arm) is inconsistent with the number reported as randomized..
Jan 7
Late Vahedian-Azimi et al., Nutrients, doi:10.3390/nu14020256 Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials
Details   Review of 6 COVID-19 curcumin studies showing that treatment resulted in significant improvement in symptoms, duration of hospitalization, and mortality, and a significant decrease in proinflammatory cytokines and increase in anti-inflamm..
Dec 27
Early Bhardwaja et al., Research Square, doi:10.21203/ (Preprint)
no disch., ↓36.8%, p=0.67
An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial.
Details   Small RCT with 39 patients treated with NOQ19 and 37 placebo patients, showing improved recovery, without statistical significance. NOQ19 has multiple ingredients including curcumin and antiandrogen glycyrrhiza glabra. CTRI/2021/05/033790.
Nov 16
In Vitro Marín-Palma et al., Molecules, doi:10.3390/molecules26226900 (In Vitro)
In Vitro
Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms
Details   In Vitro study showing antiviral and anti-inflammatory effects of curcumin during SARS-CoV-2 infection. Inhibition was seen with Vero E6 cells pre-infection and post-infection, and with D614G and the delta variant. The anti-inflammatory e..
Nov 14
In Vitro Bahun et al., Food Chemistry, doi:10.1016/j.foodchem.2021.131594 (In Vitro)
In Vitro
Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols
Details   In Silico and In Vitro study of plant polyphenols identifying quercetin, curcumin, ellagic acid, epigallocatechin gallate and resveratrol as SARS-CoV-2 3CLpro inhibitors with IC50 between 11.8µM and 23.4µM. Real-time binding was analyzed..
Oct 22
In Silico Singh et al., Computers in Biology and Medicine, doi:
In Silico
Potential of turmeric-derived compounds against RNA‐dependent RNA polymerase of SARS‐CoV‐2: An in-silico approach
Details   In Silico study showing strong binding affinity of curcumin and diacetylcurcumin with SARS-CoV-2 RNA‐dependent RNA polymerase. Comparison with remdesivir and favipiravir suggested greater potential of these compounds as an RdRp inhibitor.
Oct 11
Early Majeed et al., Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545
ventilation, ↓66.2%, p=1.00
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients
Details   RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.
Sep 23
In Vitro Bormann et al., Viruses, doi:10.3390/v13101914 (In Vitro)
In Vitro
Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro
Details   In Vitro study showing curcumin neutralizes SARS-CoV2 in vitro with low subtoxic concentrations. Authors note that the clinical use of curcumin is hindered by poor bioavailability, and recommend using methods to increase bioavailability s..
Sep 19
Late Hassaniazad et al., Phytotherapy Research, doi:10.1002/ptr.7294
SpO2 imp., ↑45.7%, p=0.90
A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
Details   Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune re..
Sep 8
Late Chabot et al., Cureus, doi:10.7759/cureus.17829 Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia
Details   Small case study of 2 patients, showing significant improvement in taste and smell shortly after one dose of a turmeric supplement. Authors note that the risk of one dose is low in healthy individuals not on medications metabolized by cyt..
Aug 10
Early Sankhe et al., Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6
death, ↓88.9%, p=0.12
A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID
Details   RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245.
Jul 9
N/A Panda et al., Medicine, doi:10.1097/MD.0000000000026601 The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
Details   Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability.
Jun 29
In Vitro Guijarro-Real et al., Foods, doi:10.3390/foods10071503 (In Vitro)
In Vitro
Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
Details   In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLpro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLpro activity, but did not fully account for the inhibitory effect of turmeric rh..
Jun 19
Early Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226
hosp., ↓85.7%, p=0.24
Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
Details   RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
Jun 17
In Vitro Goc et al., PLOS ONE, doi:10.1371/journal.pone.0253489 (In Vitro)
In Vitro
Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions
Details   In Vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen fo..
Jun 15
In Vitro Kandeil et al., Pathogens, doi:10.3390/pathogens10060758 (In Vitro)
In Vitro
Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2
Details   Vero E6 In Vitro study showing curcumin, hesperidin, and quercetin significantly inhibited SARS-CoV-2 replication, and In Silico analysis with promising Mpro and spike docking results.
May 28
Early Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362
death, ↓81.8%, p=0.02
Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Details   RCT 140 patients, 70 treated with curcumin and piperine (for absorption), showing faster recovery, lower progression, and lower mortality with treatment. Control group partients also received probiotics. CTRI/2020/05/025482.
May 7
Review Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review)
Curcumin as a Potential Treatment for COVID-19
Details   Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects.
Mar 28
Late Tahmasebi et al., Life Sciences, doi:10.1016/j.lfs.2021.119437
death, ↓83.3%, p=0.11
Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
Details   RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin).
Jan 3
Early Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004
progression, ↓94.3%, p=0.001
Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
Details   Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
Nov 16
Early Dound et al., Journal of Clinical Trials, S3:004
6 pt. scale, ↓33.3%, p=0.0001
A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19)
Details   RCT 200 COVID-19 positive patients in India, 100 treated with Curcumin, Vitamin C, Vitamin K2-7, and L-Selenomethionine, showing faster recovery with treatment.
Nov 13
Review Kritis et al., Metabolism Open, doi:10.1016/j.metop.2020.100066 (Review)
The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19
Details   Review of the potential benefits of bromelain and curcumin for COVID-19, and potential synergistic effects of the combination.
Oct 20
Late Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088
death, ↓50.0%, p=0.30
Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Details   Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR..
Jun 4
Theory Hooper, P., Cell Stress and Chaperones, doi:10.1007/s12192-020-01126-9 (Theory)
COVID-19 and heme oxygenase: novel insight into the disease and potential therapies
Details   Proposal that COVID-19 risk is related to low intracellular heme oxygenase (HO-1), and that therapies that raise HO-1 may be beneficial, which includes fluvoxamine, certain anesthetics (sevoflurane or isoflurane), hemin, estrogen, statins..
Apr 24
In Silico Sekiou et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 (Preprint)
In Silico
In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2
Details   In Silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.